Evaluating the Effects of Melatonin Supplementation on Anxiety and Depression in Patients with Breast Cancer

Phase 3

Recruiting

• Conditions: Condition 1: Anxiety. Condition 2: Depression. Condition 3: Breast Cancer. Condition 4: Mixed Anxiety and Depression.; Adjustment disorder with anxiety; F43.23; F43.22; Adjustment disorder with depressed mood; Malignant neoplasm of breast; F43.21; Adjustment disorder with mixed anxiety and depressed mood

• Registration Number: IRCT20240304061165N1
• Lead Sponsor: Sabzevar University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 76

Inclusion Criteria

Informed consent to participate in the study.
Patients with breast cancer under follow-up who have been treated for three months based on pathology results and were disease-free at the time of examination.
People without diabetes, high blood pressure, cardiovascular diseases, kidney disease, liver disease, acute diseases, autoimmune disease, thyroid disorder, mental disorders

Exclusion Criteria

Patients with known underlying diseases including uncontrolled diabetes, uncontrolled high blood pressure, cardiovascular diseases, chronic kidney disease, chronic liver disease, autoimmune disease, thyroid disorder, and the use of uncontrolled psychiatric drugs.
Unwillingness to continue cooperation in the project
Diagnosis of metastasis
Causing severe toxicities that could not be controlled with usual doses, such as nausea

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Depression. Timepoint: Day 0 and 30 of intervention. Method of measurement: Beck's Depression Inventory (BDI).;Anxiety. Timepoint: Day 0 and 30 of intervention. Method of measurement: Beck's Anxiety Inventory (BAI).